Cargando…
Safety of Tenofovir Disoproxil Fumarate–Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis
BACKGROUND: There are limited data on adverse effects of tenofovir disoproxil fumarate (TDF)-based antiretroviral therapy (ART) on pregnant women and their infants. METHODS: We conducted a systematic review of studies published between January 1980 and January 2017 that compared adverse outcomes in...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JAIDS Journal of Acquired Immune Deficiency Syndromes
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553236/ https://www.ncbi.nlm.nih.gov/pubmed/28291053 http://dx.doi.org/10.1097/QAI.0000000000001359 |
_version_ | 1783256595471269888 |
---|---|
author | Nachega, Jean B. Uthman, Olalekan A. Mofenson, Lynne M. Anderson, Jean R. Kanters, Steve Renaud, Francoise Ford, Nathan Essajee, Shaffiq Doherty, Meg C. Mills, Edward J. |
author_facet | Nachega, Jean B. Uthman, Olalekan A. Mofenson, Lynne M. Anderson, Jean R. Kanters, Steve Renaud, Francoise Ford, Nathan Essajee, Shaffiq Doherty, Meg C. Mills, Edward J. |
author_sort | Nachega, Jean B. |
collection | PubMed |
description | BACKGROUND: There are limited data on adverse effects of tenofovir disoproxil fumarate (TDF)-based antiretroviral therapy (ART) on pregnant women and their infants. METHODS: We conducted a systematic review of studies published between January 1980 and January 2017 that compared adverse outcomes in HIV-infected women receiving TDF- vs. non–TDF-based ART during pregnancy. The risk ratio (RR) for associations was pooled using a fixed-effects model. RESULTS: Seventeen studies met the study inclusion criteria. We found that the rate of preterm (<37 weeks gestation) delivery (RR = 0.90, 95% confidence interval [CI]: 0.81 to 0.99, I(2) = 59%) and stillbirth (RR = 0.60, 95% CI: 0.43 to 0.84, I(2) = 72.0%) were significantly lower in women exposed (vs. not) to TDF-based ART regimen. We found no increased risk in maternal severe (grade 3) or potentially life-threatening (grade 4) adverse events (RR = 0.62; 95% CI: 0.30 to 1.29), miscarriage (RR = 1.09; 95% CI: 0.80 to 1.48), very preterm (<34 weeks gestation) delivery (RR = 1.08, 95% CI: 0.72 to 1.62), small for gestational age (RR = 0.87, 95% CI: 0.67 to 1.13), low birth weight (RR = 0.91; 95% CI: 0.80 to 1.04), very low birth weight (RR = 3.18; 95% CI: 0.65 to 15.63), congenital anomalies (RR = 1.03; 95% CI: 0.83 to 1.28), infant adverse outcomes or infant mortality (age >14 days) (RR = 0.65; 95% CI: 0.23 to 1.85), but increased neonatal mortality (age <14 days) risk (RR = 5.64, 95% CI: 1.70 to 18.79) with TDR-based ART exposure. No differences were found for anthropomorphic parameters at birth; one study reported minor differences in z-scores for length and head circumference at age 1 year. CONCLUSIONS: TDF-based ART in pregnancy seems generally safe for women and their infants. However, data remain limited and further studies are needed, particularly to assess neonatal mortality and infant growth/bone effects. |
format | Online Article Text |
id | pubmed-5553236 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | JAIDS Journal of Acquired Immune Deficiency Syndromes |
record_format | MEDLINE/PubMed |
spelling | pubmed-55532362017-08-31 Safety of Tenofovir Disoproxil Fumarate–Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis Nachega, Jean B. Uthman, Olalekan A. Mofenson, Lynne M. Anderson, Jean R. Kanters, Steve Renaud, Francoise Ford, Nathan Essajee, Shaffiq Doherty, Meg C. Mills, Edward J. J Acquir Immune Defic Syndr Critical Review BACKGROUND: There are limited data on adverse effects of tenofovir disoproxil fumarate (TDF)-based antiretroviral therapy (ART) on pregnant women and their infants. METHODS: We conducted a systematic review of studies published between January 1980 and January 2017 that compared adverse outcomes in HIV-infected women receiving TDF- vs. non–TDF-based ART during pregnancy. The risk ratio (RR) for associations was pooled using a fixed-effects model. RESULTS: Seventeen studies met the study inclusion criteria. We found that the rate of preterm (<37 weeks gestation) delivery (RR = 0.90, 95% confidence interval [CI]: 0.81 to 0.99, I(2) = 59%) and stillbirth (RR = 0.60, 95% CI: 0.43 to 0.84, I(2) = 72.0%) were significantly lower in women exposed (vs. not) to TDF-based ART regimen. We found no increased risk in maternal severe (grade 3) or potentially life-threatening (grade 4) adverse events (RR = 0.62; 95% CI: 0.30 to 1.29), miscarriage (RR = 1.09; 95% CI: 0.80 to 1.48), very preterm (<34 weeks gestation) delivery (RR = 1.08, 95% CI: 0.72 to 1.62), small for gestational age (RR = 0.87, 95% CI: 0.67 to 1.13), low birth weight (RR = 0.91; 95% CI: 0.80 to 1.04), very low birth weight (RR = 3.18; 95% CI: 0.65 to 15.63), congenital anomalies (RR = 1.03; 95% CI: 0.83 to 1.28), infant adverse outcomes or infant mortality (age >14 days) (RR = 0.65; 95% CI: 0.23 to 1.85), but increased neonatal mortality (age <14 days) risk (RR = 5.64, 95% CI: 1.70 to 18.79) with TDR-based ART exposure. No differences were found for anthropomorphic parameters at birth; one study reported minor differences in z-scores for length and head circumference at age 1 year. CONCLUSIONS: TDF-based ART in pregnancy seems generally safe for women and their infants. However, data remain limited and further studies are needed, particularly to assess neonatal mortality and infant growth/bone effects. JAIDS Journal of Acquired Immune Deficiency Syndromes 2017-09-01 2017-09-01 /pmc/articles/PMC5553236/ /pubmed/28291053 http://dx.doi.org/10.1097/QAI.0000000000001359 Text en Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Critical Review Nachega, Jean B. Uthman, Olalekan A. Mofenson, Lynne M. Anderson, Jean R. Kanters, Steve Renaud, Francoise Ford, Nathan Essajee, Shaffiq Doherty, Meg C. Mills, Edward J. Safety of Tenofovir Disoproxil Fumarate–Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis |
title | Safety of Tenofovir Disoproxil Fumarate–Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis |
title_full | Safety of Tenofovir Disoproxil Fumarate–Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis |
title_fullStr | Safety of Tenofovir Disoproxil Fumarate–Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis |
title_full_unstemmed | Safety of Tenofovir Disoproxil Fumarate–Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis |
title_short | Safety of Tenofovir Disoproxil Fumarate–Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis |
title_sort | safety of tenofovir disoproxil fumarate–based antiretroviral therapy regimens in pregnancy for hiv-infected women and their infants: a systematic review and meta-analysis |
topic | Critical Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553236/ https://www.ncbi.nlm.nih.gov/pubmed/28291053 http://dx.doi.org/10.1097/QAI.0000000000001359 |
work_keys_str_mv | AT nachegajeanb safetyoftenofovirdisoproxilfumaratebasedantiretroviraltherapyregimensinpregnancyforhivinfectedwomenandtheirinfantsasystematicreviewandmetaanalysis AT uthmanolalekana safetyoftenofovirdisoproxilfumaratebasedantiretroviraltherapyregimensinpregnancyforhivinfectedwomenandtheirinfantsasystematicreviewandmetaanalysis AT mofensonlynnem safetyoftenofovirdisoproxilfumaratebasedantiretroviraltherapyregimensinpregnancyforhivinfectedwomenandtheirinfantsasystematicreviewandmetaanalysis AT andersonjeanr safetyoftenofovirdisoproxilfumaratebasedantiretroviraltherapyregimensinpregnancyforhivinfectedwomenandtheirinfantsasystematicreviewandmetaanalysis AT kanterssteve safetyoftenofovirdisoproxilfumaratebasedantiretroviraltherapyregimensinpregnancyforhivinfectedwomenandtheirinfantsasystematicreviewandmetaanalysis AT renaudfrancoise safetyoftenofovirdisoproxilfumaratebasedantiretroviraltherapyregimensinpregnancyforhivinfectedwomenandtheirinfantsasystematicreviewandmetaanalysis AT fordnathan safetyoftenofovirdisoproxilfumaratebasedantiretroviraltherapyregimensinpregnancyforhivinfectedwomenandtheirinfantsasystematicreviewandmetaanalysis AT essajeeshaffiq safetyoftenofovirdisoproxilfumaratebasedantiretroviraltherapyregimensinpregnancyforhivinfectedwomenandtheirinfantsasystematicreviewandmetaanalysis AT dohertymegc safetyoftenofovirdisoproxilfumaratebasedantiretroviraltherapyregimensinpregnancyforhivinfectedwomenandtheirinfantsasystematicreviewandmetaanalysis AT millsedwardj safetyoftenofovirdisoproxilfumaratebasedantiretroviraltherapyregimensinpregnancyforhivinfectedwomenandtheirinfantsasystematicreviewandmetaanalysis |